NCT02168140View on ClinicalTrials.gov

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

April 18, 2019

Study Completion Date

September 15, 2022

Conditions
Adult Lymphocyte Depletion Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin LymphomaAdult Mixed Cellularity Hodgkin LymphomaAdult Nasal Type Extranodal NK/T-cell LymphomaAdult Nodular Sclerosis Hodgkin LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaHepatosplenic T-cell LymphomaNoncutaneous Extranodal LymphomaPeripheral T-cell LymphomaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Hodgkin LymphomaRecurrent Adult T-cell Leukemia/LymphomaRecurrent Cutaneous T-cell Non-Hodgkin LymphomaRecurrent Mycosis Fungoides/Sezary SyndromeT-cell Adult Acute Lymphoblastic LeukemiaT-cell Large Granular Lymphocyte Leukemia
Interventions
DRUG

6,8-bis(benzylthio)octanoic acid

Given IV

DRUG

bendamustine hydrochloride

Given IV

Trial Locations (2)

19104

Abramson Cancer Center, Philadelphia

27157

Comprehensive Cancer Center of Wake Forest University, Winston-Salem

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT02168140 - CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter